Survey of major adverse events in osteoporotic patients using eldecalcitol and bisphosphonates

Survey of major adverse events in osteoporotic patients using eldecalcitol and bisphosphonates - Survey of major adverse events in osteoporotic patients using eldecalcitol and bisphosphonates

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041937

Enrollment

3000

Registered

2020-10-01

Start date

2020-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with osteoporosis who started eldecalcitol or bisphosphonate

Exclusion criteria

Exclusion criteria: Patients whose gender and age information on the first prescription date cannot be confirmed

Design outcomes

Primary

Measure	Time frame
Number of Hypercalcemia, acute kidney injury, urinary calculus, osteonecrosis of jaw, atypical femoral fracture	—

Countries

Japan

Contacts

Public ContactSatoshi Kondo

CHUGAI PHARMACEUTICAL CO.,LTD. Medical Science Dept.

kondosts@chugai-pharm.co.jp03-3273-0866

Outcome results